• Robert Cg Martin, Bryce M Marshall, Prejesh Philips, Michael Egger, Kelly M McMasters, and Charles R Scoggins.
• Department of Surgery, Division of Surgical Oncology, University of Louisville School of Medicine, USA. Electronic address: Robert.Martin@louisville.edu.
• Am. J. Surg. 2020 Dec 1; 220 (6): 1428-1432.

IntroductionCytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) is an effective, aggressive approach to treating intraperitoneal carcinomatosis. This study aimed to test the efficacy/safety of an enhanced recovery (ERAS) program after CRS-HIPEC surgery.MethodsReview of an IRB-approved prospectively maintained HIPEC database from 2003 to 2019. Adverse events and outcomes related to the primary operation were noted.Results125 HIPEC procedures performed met inclusion criteria, with 20 treated through ERAS. There was an improvement in LOS (ERAS: 9, 6.0-28.0; non-ERAS: 11.0, 6.0-45.1, P = 0.5), a significant reduction in opioid use during hospitalization (ERAS Total Morphine Equivalents 156 vs Non-ERAS of 856, p < 0.001), and a significant reduction in discharge opioid requirements (ERAS 55% of patients, non-ERAS 97%, p < 0.02).ConclusionERAS for CRS-HIPEC is safe, while maintaining quality outcomes, and leads to significant reductions in hospital opioid use and discharge narcotic usage. Our experience supports the full implementation of an ERAS protocol for HIPEC.Copyright © 2020 Elsevier Inc. All rights reserved.

25 keywords...

hide…